RxDoctor Payments DataLook up a doctor →

Michael Lott, MD

Pain Medicine · Dallas, GANPI 1316122922

Payments from drug & device makers

$9,263in general payments, 2019–2025

Across 374 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Relievant Medsystems, Inc.$1K
  • Boston Scientific$883
  • Collegium Pharmaceutical, Inc.$871
  • Scilex Pharmaceuticals Inc.$665
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$622
  • plus $4K from 36 others

What the payments were for

  • Travel & lodging$1,04011%
  • Food & beverage$7,77284%
  • Education$4505%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,263 in reported general payments places this provider in the 85th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$430,816
Medicare patients
739
Services billed
4,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide31$88,050
BelbucaBuprenorphine Hcl63$54,422
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,491$44,151
ZtlidoLidocaine48$33,841
MovantikNaloxegol Oxalate74$30,957
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen982$19,107
Gabapentin1,120$14,381
Pregabalin549$12,609
Buprenorphine32$8,942
Oxycodone Hcl452$8,099
SymproicNaldemedine Tosylate14$6,001
Lidocaine49$5,759
Morphine Sulfate ErMorphine Sulfate234$5,082
Tramadol Hcl628$4,201
Diclofenac Sodium80$3,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$622$88,05031 claims
Collegium Pharmaceutical, Inc.Belbuca$871$54,42263 claims
Scilex Pharmaceuticals Inc.Ztlido$665$33,84148 claims
Redhill Biopharma Inc.Movantik$23$30,95774 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Dallas

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →